share_log

Inhibikase Therapeutics To Present Data From Phase 1/1b Study Of IkT-148009 At The Movement Disorders Society Congress

Inhibikase Therapeutics To Present Data From Phase 1/1b Study Of IkT-148009 At The Movement Disorders Society Congress

Inhibikase治療公司將在運動障礙學會大會上公佈IKT-148009的1/1b期研究數據
Benzinga Real-time News ·  2022/09/15 08:07

IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system (CNS) in older and elderly healthy volunteers and Parkinson's patients

在老年健康志願者和帕金森病患者中,IKT-148009耐受性良好,全身暴露高,並持續滲透到中樞神經系統(CNS)

No clinically significant adverse events observed

未觀察到有臨牀意義的不良反應

Actively enrolling Phase 2a '201' clinical trial of IkT-148009 in patients with untreated Parkinson's disease

在初治帕金森病患者中積極納入IKT-148009的2a‘201’期臨牀試驗

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論